April 19, 2023 -Successful completion of recent audit demonstrates MolecuLight’s commitment to data security
TORONTO, ON – (April 19, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced that it is in compliance with SOC 2® Type I, having successfully
… Read MoreFebruary 14, 2023 -Findings from a New Clinical Study Using MolecuLight Imaging of Diabetic Foot Ulcers Prompts New Diagnostic Terminology Enabling Proactive Infection Management
TORONTO, ON – (February 14, 2023) MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced the publication
… Read MoreDecember 6, 2022 -Article is a Follow-On to MolecuLight’s Receipt an Innovative Technology Contract from Vizient Last Year
PITTSBURGH, PA – (December 6, 2022) MolecuLight Corp., the leader in point-of-care fluorescence imaging for detection of wounds containing elevated bacterial loads, is featured in Vizient’s newly released Tech Watch publication as a
… Read MoreNovember 10, 2022 -Unprecedented Body of New Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision-Making and Patient Outcomes
Toronto, CANADA and Salt Lake City, UTAH – (November 10, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that
… Read MoreOctober 13, 2022 -Unprecedented Body of New Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates Improved Clinical Decision-Making and Patient Outcomes
Toronto, CANADA and Las Vegas, NEVADA – (October 13, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, announces that over
… Read MoreSeptember 29, 2022 -Contract Awarded for Products that Bring Improvement to the Health Care Industry
PITTSBURGH, PA (September 29, 2022) –MolecuLight Corp., the leader in point-of-care fluorescence imaging for the real-time detection of bacteria in wounds, announces it has been awarded a new group purchasing agreement with AllSpire Health
… Read MoreSeptember 13, 2022 -Wide-Spread Clinical Evidence using the MolecuLight Wound Imaging Platform Demonstrates its Significant Global Adoption and Proven Utility in Wound Care
Toronto, CANADA and Sydney, AUSTRALIA – (September 13, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that its
… Read MoreAugust 11, 2022 -New Financing to Meet Significant Growth in Global Demand for MolecuLight’s i:X® and DX™ Point-of-Care Imaging Devices for the Wound Care Industry
Toronto, CANADA – (August 11, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced that it has
… Read MoreJuly 13, 2022 -Study Confirms the Utility of MolecuLight to Inform Clinicians to the Presence and Location of Clinically Significant Bacteria and Improves Treatment Plans & Outcomes over Conventional Diagnostic Methods
Leeds, UK and Toronto, CANADA – (July 13, 2022) MolecuLight Inc., the leader in fluorescence imaging for detection and localization of
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s
Technology
Breakthrough Designation
MolecuLight
i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2026
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.